AEterna Zentaris (TSX:AEZS) Gross-Profit-to-Asset %

: 0.66% (As of Dec. 2023)

View and export this data going back to 1995. Start your Free Trial

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. AEterna Zentaris's annualized Gross Profit for the quarter that ended in Dec. 2023 was C$0.36 Mil. AEterna Zentaris's average Total Assets over the quarter that ended in Dec. 2023 was C$53.57 Mil. Therefore, AEterna Zentaris's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 was 0.66%.

AEterna Zentaris Gross-Profit-to-Asset % Historical Data

The historical data trend for AEterna Zentaris's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AEterna Zentaris Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Gross-Profit-to-Asset %

Get a 7-Day Free Trial

0.54

4.64

8.83

8.34

9.12

AEterna Zentaris Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Gross-Profit-to-Asset %	Get a 7-Day Free Trial															16.04	15.79	16.97	-0.07	0.66

Competitive Comparison

For the Biotechnology subindustry, AEterna Zentaris's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AEterna Zentaris Gross-Profit-to-Asset % Distribution

For the Biotechnology industry and Healthcare sector, AEterna Zentaris's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where AEterna Zentaris's Gross-Profit-to-Asset % falls into.

AEterna Zentaris Gross-Profit-to-Asset % Calculation

AEterna Zentaris's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Dec. 2023 )	/	( (Total Assets (A: Dec. 2022 )	+	Total Assets (A: Dec. 2023 ))	/ count )
	=	5.737	/	( (76.111	+	49.661)	/ 2 )
	=	5.737	/	62.886
	=	9.12 %

AEterna Zentaris's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Dec. 2023 )	/	( (Total Assets (Q: Sep. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
	=	0.356	/	( (57.488	+	49.661)	/ 2 )
	=	0.356	/	53.5745
	=	0.66 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Dec. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

AEterna Zentaris Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of AEterna Zentaris's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

AEterna Zentaris (TSX:AEZS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AEterna Zentaris Inc (TSX:AEZS) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

AEZS:USA ET8:Germany

Address

222 Bay Street, Suite 3000, PO Box 53, c/o Norton Rose Fulbright Canada, LLP, Toronto, ON, CAN, M5K 1E7

Website

https://www.zentaris.com

AEterna Zentaris Inc is a biopharmaceutical company commercializing & developing therapeutics & diagnostic tests. The company's product, Macrilen (macimorelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (GHD). Macrilen is marketed in the U.S. through a license agreement with Novo Nordisk & the company receives royalties on sales. Aeterna owns all rights to macimorelin outside of the U.S. & Canada. It is leveraging the clinical success & safety profile of macimorelin to develop it for the diagnosis of child-onset GHD. The company's geographical segments include Switzerland, Ireland, Denmark, and others, of which nearly all of its revenue comes from Switzerland.